Applications of Akkermansia muciniphila in preparing microecological preparations for treating or preventing avian influenza virus infection

A technology of avian influenza virus and microecological preparations, applied in the direction of antiviral agents, medical raw materials derived from bacteria, dispersion liquid delivery, etc., can solve problems such as changes in vaccine protection effects, and achieve the goals of improving weight loss, inhibiting proliferation, and increasing survival rate Effect

Active Publication Date: 2020-05-22
HUAZHONG AGRI UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the current vaccination has played a very good role in controlling H7N9 influenza, the protective effect of the vaccine is also changing with the high variability of influen...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of Akkermansia muciniphila in preparing microecological preparations for treating or preventing avian influenza virus infection
  • Applications of Akkermansia muciniphila in preparing microecological preparations for treating or preventing avian influenza virus infection
  • Applications of Akkermansia muciniphila in preparing microecological preparations for treating or preventing avian influenza virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The preparation method of the probiotic preparation of anti-avian influenza virus infection:

[0029] 1. Preparation of pasteurized Akkermansia muciniphila preparations

[0030] Akkermansia muciniphila ATCC BAA-835. The lyophilized powder of the strain was resuspended with sterile PBS, and an appropriate amount of bacterial solution was picked with an inoculation loop to be rejuvenated by streaking on the BD company's brain heart infusion (BHI) agar supplemented with 0.25% mucin (Sigma) Incubate at 37°C for 48h under oxygen condition. Wash the bacterial colony with 1mL PBS, collect the bacterial suspension; take 50 μL of the bacterial suspension and spread it evenly on the BHI agar containing 0.25% mucin, and cultivate it under anaerobic conditions at 37°C for 48 hours; Rinse the bacterial lawn, collect the bacterial suspension, centrifuge at 4°C and 5000rpm for 10 minutes, discard the supernatant, resuspend the collected Akkermansia muciniphila pellet in PBS, count o...

Embodiment 2

[0033] Effects of Akkermansia muciniphila ATCC BAA-835 on the mortality and body weight of mice infected with H7N9 avian influenza virus

[0034] 1. Effects on Mortality and Body Weight of SPF Mice

[0035]The experimental animals were 8-week-old female C57BL / 6 specific pathogen-free (SPF) mice, a total of 30 were randomly divided into 3 groups, 10 in each group, and all animals were raised in a biosafety level 3 laboratory (ABSL3) . The first group is the control group fed with sterile PBS, 200ul per mouse; the second group is the group fed with live Akkermansia muciniphila (Akkermansia muciniphila) ATCC BAA-835 preparation, 200ul per mouse ; The third group was fed with pasteurized Akkermansia muciniphila (Akkermansia muciniphila) ATCC BAA-835 group, 200ul per mouse

[0036] Antibiotic treatment: Before the probiotic preparations were fed to the test mice, the mice were treated with a compound antibiotic solution, and the compound antibiotics were added to the sterile wate...

Embodiment 3

[0047] The effect of the inactivated probiotic preparation prepared in Example 1 on the influenza virus content in the lungs of mice after H7N9 avian influenza virus infection, the impact on the tissue structure of the lungs of mice, and the impact on the contents of lung cytokines and blood cytokines.

[0048] The 36 SPF mice were randomly divided into 2 groups, 18 in each group. The first group was fed with sterile PBS control group, 200ul per mouse; the second group was fed with pasteurized mucin A For Akkermansia muciniphila ATCC BAA-835 group, 200ul per mouse;

[0049] As in Example 2, all SPF mice were raised in a biosafety level three laboratory (ABSL3), and underwent the same steps of antibiotic treatment, probiotic preparation gavage and H7N9 influenza virus infection.

[0050] Lung tissue processing: Lung samples were dissected on day 0, day 3, and day 5 after infection, with 5 mice per group at each time point. Add 1ml PBS to each lung for homogenization, centrifug...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of biological preparations, and specifically discloses applications of Akkermansia muciniphila in preparing microecological preparations for treating or preventing avian influenza virus infection. Intervention is performed on mice with pasteurized Akkermansia muciniphila; and through the infection of H7N9 influenza viruses, aspects such as the survival rates, weight changes, virus content in lungs, lung pathological changes and lung cytokine levels of the mice in each group can be assessed. Through the indication of results, the pasteurized Akkermansia muciniphila can significantly improve weight loss and lung tissue damage caused by H7N9 influenza virus infection, inhibit the reproduction of lung viruses and significantly enhance the survival rates of the mice infected with the H7N9 influenza viruses; prepared microecological preparations are safe and have no toxic and side effects, and are more convenient to store compared with other live bacteria microecological preparations; and thus, important technical support can be provided for the development of novel anti-influenza preparations.

Description

technical field [0001] The invention relates to the field of biological agents against influenza virus infection, in particular to the application of Akkermansia muciniphila in the preparation of probiotics for treating or preventing avian influenza virus infection. Background technique [0002] Influenza is a worldwide infectious viral disease caused by influenza virus, a single-stranded negative-sense RNA virus (Steinhauer and Skehel 2002), belonging to the Orthomyxoviridae family. Influenza viruses cause approximately 1 billion infections worldwide, resulting in annual and intermittent epidemics (Chen et al 2017). Also, it is highly variable and can continuously recombine to form new subtypes. [0003] The importance of the gut microbiota has been widely recognized, and changes in the gut microbiota not only affect local cellular functions and immune responses, but also play an important role in respiratory diseases (Marsland et al 2015). A growing body of research has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/74A61P31/16
CPCA61K9/0095A61K35/74A61P31/16
Inventor 金梅林胡晓通张强杨丽王婷孙小美康超钟鸣
Owner HUAZHONG AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap